Company: BWAY
Filing Date: 2025-09-30
Form Type: 6-K
Source: 0001171843-25-006185
Chunk: 5

Company: Brainsway Ltd.
Filing Date: 2025-09-30
Form: 6-K
Chunk 5
---
   |     |   |        |   |
| Right-of-use assets recognized with corresponding lease liability             |     | $                                 |     197 |   |     | $ |    181 |   |
| Change in prepaid expenses recognized with corresponding liability            |     | $                                 |   1,487 |   |     | $ |      — |   |

<div align='center'>The accompanying Notes are an integral part of these condensed consolidated
unaudited interim Financial Statements.</div>

| 5 |

<div align='center'>BRAINSWAY LTD. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED INTERIM FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)</div>

NOTE 1: GENERAL

| a. | A general description of the Company and its activity: |

BrainsWay Ltd. (the “Company”) is a leader in
advanced non-invasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary
Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. The Company has obtained
from the U.S. Food and Drug Administration (FDA) three cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
Current indications include MDD (Major Depressive Disorder), obsessive-compulsive disorder (OCD), and smoking addiction.

The Company received its first commercial Deep TMS
product clearance from the FDA in 2013, for the treatment of MDD in adult patients who have failed to achieve satisfactory
improvement from anti-depressant medication. In April 2021, the Company received FDA clearance for a shorter innovative MDD
treatment and in August 2021, the Company received an additional clearance from the FDA for expansion of the existing MDD clearance
to include the non-invasive treatment of anxiety symptoms. In 2022, the Company extended its FDA clearance for MDD (including
anxious depression) to our H7 Coil, also via the 510(k) process. In May 2024, the FDA cleared an expansion of the Company’s
MDD clearance allowing for the treatment of patients with late life depression. The expanded clearance covers MDD patients ages 22
to 86, changing the previous upper age limit of 68.

The Company received de novo clearance from the
FDA in August 2018 for use of its Deep TMS as an adjunct therapy